(Q34311097)

1 August 2017

Viruses in cancer treatment (English)

1 reference

1 August 2017

R Alemany

1

1 reference

1 August 2017

10 November 2012

1 reference

Clinical and Translational Oncology

1 August 2017

1 reference

1 August 2017

15

1 reference

1 August 2017

182-188

1 reference

1 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-012-0951-7

1 August 2017

0 references

cites work

The history of tumor virology

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Stem cell collection and gene transfer in Fanconi anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Oncolytic viruses from the perspective of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

An optimized clinical regimen for the oncolytic virus PV701.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Therapeutic potential of oncolytic measles virus: promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Studies on the use of viruses in the treatment of carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

21 January 2018

Oncolytic virotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Do we need a different set of response assessment criteria for tumor immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Intelligent design: combination therapy with oncolytic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Tropism-modification strategies for targeted gene delivery using adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Evolution of oncolytic adenovirus for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Thunder and lightning: immunotherapy and oncolytic viruses collide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

Immunodominance: a pivotal principle in host response to viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0951-7

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

21 January 2018

1 reference

12 December 2020

Human cancer vaccines

1 reference

12 December 2020

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

1 reference

12 December 2020

Safety and clinical usage of newcastle disease virus in cancer therapy

1 reference

12 December 2020

History of oncolytic viruses: genesis to genetic engineering

1 reference

12 December 2020

10.1007/S12094-012-0951-7

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

23143950